Drug Profile
Research programme: respiratory disorder therapeutics - Adams Respiratory/Aquestive Therapeutics
Latest Information Update: 22 Jan 2018
Price :
$50
*
At a glance
- Originator Adams Respiratory Therapeutics; MonoSol Rx LLC
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Respiratory tract disorders
Most Recent Events
- 27 Mar 2007 Preclinical trials in Respiratory tract disorders in USA (PO)